Drug intelligence / Profile preview

SLTE-2100

Development stage: Preclinical
Lead developer: Slate Medicines
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

SLTE-2100 is a bispecific antibody being developed by Slate Medicines for the treatment of migraine and other headache disorders. It is designed to simultaneously target two key biological pathways involved in headache pathophysiology: the pituitary adenylate cyclase-activating polypeptide (PACAP) / vasoactive intestinal peptide (VIP) pathway and the calcitonin gene-related peptide (CGRP) pathway. By dual-targeting these neuropeptides, SLTE-2100 aims to provide enhanced efficacy compared to therapies targeting a single pathway. As of mid-2026, the program is in the lead optimization stage, with clinical trials anticipated to commence in the second half of 2027.

Targets

Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide receptor pathway (PACAP/VIP pathway)CGRP (Calcitonin gene-related peptide)

Beyond the preview

Go deeper on SLTE-2100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLTE-2100.

Explore the full profile